Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27634687 | 0.74 | HTR2C (0.53) | PBRM1TNKS2HTR2CGSK3BBACE1 | |
| SCHEMBL18752770 | 0.74 | PBRM1 (0.70) | PBRM1TNKS2HTR2CGSK3BBACE1 | |
| SCHEMBL8220805 | 0.71 | NPC1 (0.39) | TNKS2ALDH1A1 | |
| SCHEMBL13170398 | 0.71 | HTR2C (0.50) | PBRM1TNKS2HTR2CGSK3BBACE1 | |
| SCHEMBL10801423 | 0.70 | NPSR1 (0.55) | PBRM1TNKS2HTR2CGSK3BBACE1 | |
| SCHEMBL17393757 | 0.67 | ACHE (0.47) | PBRM1TNKS2HTR2CTSHRACHE | |
| SCHEMBL13189805 | 0.67 | HTR2C (0.50) | PBRM1TNKS2HTR2CTSHRACHE | |
| SCHEMBL9805304 | 0.67 | HTR2C (0.50) | PBRM1TNKS2HTR2CGSK3BBACE1 | |
| SCHEMBL10331631 | 0.67 | HTR2C (0.50) | PBRM1TNKS2HTR2CTSHRACHE | |
| SCHEMBL14290349 | 0.67 | HTR2C (0.50) | PBRM1TNKS2HTR2CTSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9238039-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | PBRM1 2062/4885TNKS2 1971/4885HTR2C 3916/4885 |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | PBRM1 2062/4885TNKS2 1971/4885HTR2C 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.